Abstract
Triple negative breast cancer (TNBC) represents the most malignant subtype of breast cancer, and yet our understanding about its unique biology remains elusive. We have conducted a comparative computational analysis of transcriptomic data of TNBC and non-TNBC (NTNBC) tissue samples from the TCGA database, focused on genes involved in neural functions. Our main discoveries are: (1) while both subtypes involve neural functions, TNBC has substantially more up-regulated neural genes than NTNBC, suggesting that TNBC is more complex than NTNBC; (2) non-neural functions related to cell-microenvironment interactions and intracellular damage processing are key inducers of the neural genes in both TNBC and NTNBC, but the inducer-responder relationships are different in the two cancer subtypes; (3) key neural functions such as neural crest formation are predicted to enhance adaptive immunity in TNBC while glia development, along with a few other neural functions, induce both innate and adaptive immunity in NTNBC. These results reveal key differences in the biology between the two cancer subtypes, particularly in terms of the roles that neural functions play.
Introduction
Triple Negative Breast Cancer (TNBC) is characterized by its aggressive nature and the absence of estrogen, progesterone, and HER2 receptors, making it resistant to standard targeted therapies. Recent research has begun to explore the role of "neo-neurogenesis"—the process by which tumors mimic or recruit nervous system functions—to facilitate growth and metastasis. This study investigates whether neural gene expression in breast cancer is merely incidental or if it serves a distinct functional purpose that varies between TNBC and non-TNBC (NTNBC) subtypes.
Methodology
Researchers utilized transcriptomic data from The Cancer Genome Atlas (TCGA), comparing 119 TNBC tumor samples and 1,066 NTNBC samples against their respective healthy controls. The analysis involved:
- Differential Expression Analysis: Identifying up-regulated neural-related genes.
- Pathway Enrichment: Categorizing genes into functional groups using Gene Ontology (GO).
- Regression Modeling: Using generalized linear regression (Lasso/Ridge) to identify "inducer-responder" relationships, where non-neural biological processes (inducers) statistically explain the activation of neural pathways (responders).
Key Results
TNBC is "Neurally Hyperactive"
The study found that TNBC is significantly more neurally complex than NTNBC. TNBC involved 589 enriched neural pathways compared to only 220 in NTNBC. Notably, TNBC heavily utilizes "late-stage" neural functions, such as neurotransmitter secretion and synapse formation (Group 4), which are largely absent in NTNBC.
Distinct Biological Triggers and Immune Modulation
The regression analysis revealed that neural genes are triggered by different environmental cues in each subtype. In TNBC, neural activation is primarily driven by cell-environment interactions (e.g., cell adhesion). In contrast, NTNBC neural genes are largely a response to intracellular damage processing and DNA repair mechanisms.
Furthermore, the impact on the immune system is subtype-specific. In TNBC, neural crest formation pathways are predicted to enhance adaptive immunity, potentially helping the tumor manage the host's immune response. In NTNBC, glia development plays a similar role in modulating both innate and adaptive immunity.
Stage-Specific Dynamics
As TNBC progresses from primary tumors (T-stages) to lymph node involvement (N-stages), the variety of neural functions decreases, but the remaining active pathways become more tightly integrated with cell adhesion and organelle assembly, suggesting a refinement of neural mimicry to support metastasis.
Discussion and Future Directions
While these computational findings provide a robust statistical framework for understanding the "dark matter" of TNBC biology, they represent predicted causal relationships. Future wet-lab validation using in vivo or in vitro models is essential to confirm these inducer-responder links. If validated, these findings suggest that existing neurological drugs targeting neurotransmitters or synaptic functions could potentially be repurposed as novel therapeutic strategies to "unplug" the neural support systems of aggressive breast cancers.
Summary updated